BMI stock forecast, quote, news & analysis

Technical Analysis (Indicators)

Bearish Trend Analysis

BMI moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.

The Aroon Indicator for BMI entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMI as a result. In 60 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.

The Moving Average Convergence Divergence (MACD) for BMI just turned positive on October 09, 2026. Looking at past instances where BMI's MACD turned positive, the stock continued to rise in 35 of 48 cases over the following month. The odds of a continued upward trend are 73%.

Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMI advanced for three days, in 185 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BMI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.476) is normal, around the industry mean (1.726). P/E Ratio (30.002) is within average values for comparable stocks, (7.326). Projected Growth (PEG Ratio) (2.931) is also within normal values, averaging (5.470). Dividend Yield (0.014) settles around the average of (0.011) among similar stocks. P/S Ratio (4.255) is also within normal values, averaging (32.028).

The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.